Bloomberg -- Pfizer Inc. and Bristol-Myers Squibb Co.’s experimental blood thinner apixaban topped Sanofi-Aventis SA’s Lovenox at preventing deadly clots in hip-surgery patients, according to a study. The trial of 5,407 patients found that those given the pill apixaban were 64 percent less likely to develop clots in their legs or die than those given injections of Lovenox, the standard treatment.
